Duvelisib (IPI-145) is an inhibitor that targets the PI3K isoforms delta and gamma, and exhibits anticancer activity in primary chronic lymphocytic leukaemia (CLL) cells while normal B cells remain unscathed by its cytotoxic effects [93]. This evidence concerns the gene PIK3CG and B-cell chronic lymphocytic leukemia.